Metraipolis › archive › dc_f43c076bc2eb

Characterizing bleeding adverse events associated with BCR-ABL tyrosine kinase inhibitors: insights from FAERS reports — Europe PMC PMID:42780512

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42780512
DOI
10.3389/fonc.2026.1912458
License (as archived)
solo-consultazione
Archived
2026-10-07T19:41:10.032Z
SHA-256 of the archived text
b64da161e12dc66aedeafed4a4518e5bde721a9b429047032b6d6b6c917edf74
Stable URL of this page
https://metraipolis.com/documento/dc_f43c076bc2eb

How to cite

Characterizing bleeding adverse events associated with BCR-ABL tyrosine kinase inhibitors: insights from FAERS reports — Europe PMC PMID:42780512 — Europe PMC (en), https://europepmc.org/article/MED/42780512 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f43c076bc2eb (Metraipolis archive dc_f43c076bc2eb, sha256 b64da161e12dc66aedeafed4a4518e5bde721a9b429047032b6d6b6c917edf74)
BibTeX
@misc{dcf43c076bc2eb,
  title = {Characterizing bleeding adverse events associated with BCR-ABL tyrosine kinase inhibitors: insights from FAERS reports — Europe PMC PMID:42780512},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42780512},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f43c076bc2eb; sha256 b64da161e12dc66aedeafed4a4518e5bde721a9b429047032b6d6b6c917edf74},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42780512. Agents can read the archived copy with the MCP tool read_document.